デジタル病理学市場：製品別（スキャナ、ソフトウェア、ストレージシステム）、タイプ別（ヒト、獣医）、用途別（遠隔医療、トレーニング、疾病診断、創薬）、エンドユーザー別（製薬＆バイオテクノロジー、学術機関、病院）-2028年までの世界予測

Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsulation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2028

世界のデジタル病理学市場は、予測期間中に13.6%のCAGRで、2023年の9億米ドルから2028年には18億米ドルに達すると予測されている。デジタルパソロジー市場の成長は、主に医薬品開発におけるデジタルパソロジーの... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年6月15日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	265	296	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のデジタル病理学市場は、予測期間中に13.6%のCAGRで、2023年の9億米ドルから2028年には18億米ドルに達すると予測されている。デジタルパソロジー市場の成長は、主に医薬品開発におけるデジタルパソロジーの用途の拡大、新興国における早期がん診断に対する意識の高まり、がん検診の推奨といった要因によってもたらされる。
一方、デジタル病理システムのコストが高いため、市場の成長はある程度抑制されると予想される。

ソフトウェア分野は予測期間中に最も高いCAGRで成長すると予測される製品別に見ると、世界のデジタル病理学市場はスキャナー、ソフトウェア、ストレージシステムに区分される。ソフトウェア分野は予測期間中に最も高いCAGRで成長すると予測されている。これは、病理医による統合ソフトウェアの高い採用率、遠隔一次診断のためのさまざまな医療施設でのデジタル病理ソフトウェアソリューションの採用増加によるものと考えられる。
予測期間中、ヒト病理学セグメントが最も高いCAGRで成長すると予測される。タイプ別に見ると、デジタル病理学市場はヒト病理学と獣医病理学に区分される。2023年には、新興国における癌の早期診断に対する意識の高まりや、学術研究機関、大学、病理学研究所間の協力関係の拡大により、ヒト病理学分野が最も高いCAGRで成長すると予測される。

創薬分野は予測期間中に最も高いCAGRで成長すると予測される
アプリケーション別に見ると、デジタル病理学市場は創薬、疾病診断、トレーニング＆教育に区分される。2023年には、創薬アプリケーション分野が予測期間中に最も高いCAGRで成長すると予測されている。ハイスループット・スクリーニングとイメージングにおける成長、前臨床・臨床研究数の増加が、創薬アプリケーション分野の大きなシェアと高い成長率の主な要因である。

製薬＆バイオテクノロジー企業エンドユーザー部門がデジタル病理学市場で最大シェアを占めると予測エンドユーザー別に見ると、デジタル病理学市場は製薬＆バイオテクノロジー企業、病院＆レファレンスラボラトリー、学術＆研究機関に大別される。製薬＆バイオテクノロジー企業は、デジタルパソロジー市場の最大エンドユーザーである。2023年には、薬物毒性検査におけるデジタルパソロジーの利用拡大により、製薬＆バイオテクノロジー企業セグメントがデジタルパソロジー市場で最大シェアを占めると予測されている。バイオテクノロジー企業は、バイオバンキング、バイオ医薬品研究、分子アッセイ、個別化医療の開発にデジタル病理検査を利用している。

地域別では、北米がデジタル病理学市場で最大のシェアを占めると予測されている。
地域別では、北米が2022年のデジタル病理学市場で最大のシェアを占めた。予測期間中、同市場は最も高い成長率が見込まれている。高齢者人口の増加、癌の有病率の上昇、高品質のインフラの存在、同地域における有利な償還などの要因が、北米市場の成長を促進している。

供給側の一次面接の内訳- 企業タイプ別：企業タイプ別：Tier 1 - 35%、Tier 2 - 45%、Tier 3 - 20%：Cレベル - 35％、ディレクターレベル - 25％、その他 - 40％ - 地域別：地域別：北米40％、欧州30％、アジア太平洋地域20％、中南米5％、中東・アフリカ5
デジタルパソロジー市場に参入している有力企業には、Danaher Corporation（米国）、Koninklijke Philips N.V.（オランダ）、浜松ホトニクス株式会社（日本）、F. Hoffmann-La Roche Ltd.（スイス）、3DHISTECH, Inc.(スイス)、3DHISTECH(ハンガリー)、Objective Pathology Services Limited(カナダ)、Sectra AB(スウェーデン)、OptraSCAN(米国)、Akoya Biosciences, Inc.(米国)、Glencoe Software, Inc.(米国)、Aiforia(フィンランド)、Paige AI, Inc.(米国）、富士フイルムホールディングス株式会社（日本）、Apollo Enterprise Imaging（米国）、XIFIN, Inc.（米国）、Huron Digital Pathology（カナダ）、Hologic, Inc.（米国）、Corista（米国）、Indica Labs Inc.（米国）、Proscia Inc.（米国）、KONFOONG BIOTECH INTERNATIONAL CO、LTD.(中国）、Mikroscan Technologies, Inc.（米国）、PathAI（米国）、Motic Digital Pathology（米国）、KONFOONG BIOTECH INTERNATIONAL CO.(中国）、Mikroscan Technologies, Inc.（米国）、Kanteron Systems（スペイン）。

調査範囲
本レポートでは、デジタル病理市場をタイプ、用途、製品、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）についても調査しています。市場における機会と課題を分析し、市場リーダーのための競争環境の詳細を提供しています。さらに、個々の成長動向に関してミクロ市場を分析し、主要5地域とそれぞれの国に関して市場セグメントの収益を予測しています。

レポート購入の主なメリット
本レポートは、様々なレベルの分析-業界動向、トップ企業の市場シェア、企業プロフィール-に焦点を当てており、これらを合わせて基本的な見解を形成し、競争環境、高成長地域とその促進要因、阻害要因、課題、機会を分析しています。本レポートは、既存企業だけでなく、新規参入企業/中小企業にとっても、市場の脈拍を測定し、より大きな市場シェアを獲得するのに役立ちます。
本レポートは、以下のポイントに関する洞察を提供します：

デジタル病理市場の成長に影響を与える主な促進要因（ラボの効率性を高めるためのデジタル病理導入の増加、がん罹患率の上昇、医薬品開発およびコンパニオン診断におけるデジタル病理アプリケーションの拡大、新興国における早期がん診断に対する意識の高まり、がん検診の推奨）、機会（民間病理診療所向けの手頃な価格のスキャナーの導入、個別化医療に対する需要の高まり、新興国における高い成長機会）、課題（訓練を受けた病理医の不足）の分析。

市場への浸透：世界のデジタル病理学市場のトップ企業が提供する製品ポートフォリオに関する包括的な情報を掲載しています。製品、タイプ、用途、エンドユーザー、地域別に市場を分析しています。
製品開発/イノベーション：デジタルパソロジーの世界市場における今後の動向と製品発売に関する詳細な洞察
市場開発：製品別、タイプ別、用途別、エンドユーザー別、地域別の有利な新興市場に関する包括的情報
市場の多様化：デジタルパソロジーの世界市場における新製品や製品強化、成長地域、最新動向、投資に関する詳細情報
競合評価：デジタルパソロジーの世界市場における主要企業の市場シェア、成長戦略、製品提供、競合のリーダーシップマッピング、能力に関する詳細な評価

ページTOPに戻る

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 34
1.3 MARKET SCOPE 35
1.3.1 MARKETS COVERED 35
FIGURE 1 DIGITAL PATHOLOGY MARKET 35
1.3.2 YEARS CONSIDERED 35
1.4 CURRENCY 36
1.5 STUDY LIMITATIONS 36
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 36
1.7.1 ECONOMIC RECESSION IMPACT ON DIGITAL PATHOLOGY MARKET 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH APPROACH 38
2.2 RESEARCH DESIGN 38
FIGURE 2 RESEARCH DESIGN 38
2.2.1 SECONDARY RESEARCH 39
2.2.1.1 Key data from secondary sources 40
2.2.2 PRIMARY RESEARCH 40
FIGURE 3 PRIMARY SOURCES 41
2.2.2.1 Key data from primary sources 42
2.2.2.2 Insights from primary experts 43
2.2.2.3 Breakdown of primaries 43
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43
2.3 MARKET SIZE ESTIMATION 44
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 6 DIGITAL PATHOLOGY MARKET: REVENUE SHARE ANALYSIS ILLUSTRATION OF DANAHER CORPORATION 45
FIGURE 7 BOTTOM-UP APPROACH 46
FIGURE 8 CAGR PROJECTIONS 47
FIGURE 9 IMPACT ON MARKET GROWTH AND CAGR: ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 48
2.4 DATA TRIANGULATION APPROACH 49
FIGURE 10 DATA TRIANGULATION METHODOLOGY 50
2.5 MARKET SHARE ANALYSIS 50
2.6 STUDY ASSUMPTIONS 51
2.7 RISK ASSESSMENT 51
TABLE 1 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET 51
2.8 MARKET LIMITATIONS 52
2.8.1 METHODOLOGY-RELATED LIMITATIONS 52
2.8.2 SCOPE-RELATED LIMITATIONS 52
3 EXECUTIVE SUMMARY 53
FIGURE 11 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 53
FIGURE 12 DIGITAL PATHOLOGY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 54
FIGURE 13 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 54
FIGURE 14 DIGITAL PATHOLOGY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 55
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF DIGITAL PATHOLOGY MARKET 56
4 PREMIUM INSIGHTS 57
4.1 DIGITAL PATHOLOGY MARKET OVERVIEW 57
FIGURE 16 RISING PREVALENCE OF CANCER TO DRIVE MARKET 57
4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER & COUNTRY (2022) 58
FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN DIGITAL PATHOLOGY MARKET
IN 2022 58
4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 18 UK TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 59
4.4 REGIONAL MIX: DIGITAL PATHOLOGY MARKET (2023–2028) 60
FIGURE 19 NORTH AMERICA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028) 60
4.5 DIGITAL PATHOLOGY MARKET: DEVELOPING VS. DEVELOPED MARKETS 60
FIGURE 20 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 21 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 62
5.2.1.1 Increasing adoption of digital pathology to enhance lab efficiency 62
5.2.1.2 Rising incidence of cancer 63
FIGURE 22 GLOBAL CANCER INCIDENCE, 2008–2030 63
TABLE 2 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 64
5.2.1.3 Growing applications of digital pathology in drug development and companion diagnostics 64
5.2.1.4 Growing awareness of early cancer diagnosis in emerging economies 65
5.2.1.5 Recommendations for cancer screening 66
5.2.2 RESTRAINTS 66
5.2.2.1 High cost of digital pathology systems 66
5.2.3 OPPORTUNITIES 66
5.2.3.1 Introduction of affordable scanners for private pathology practices 66
5.2.3.2 Growing demand for personalized medicine 67
TABLE 3 US: GROWTH IN NUMBER OF PERSONALIZED MEDICINES, 2008–2020 67
FIGURE 23 FDA-APPROVED PERSONALIZED MEDICINES, 2015–2021 68
5.2.3.3 High growth opportunities in emerging economies 68
5.2.4 CHALLENGES 69
5.2.4.1 Shortage of trained pathologists 69
TABLE 4 NUMBER OF INHABITANTS PER PATHOLOGIST, BY COUNTRY, 2020 69
5.3 ECOSYSTEM MARKET MAP 69
FIGURE 24 DIGITAL PATHOLOGY MARKET: ECOSYSTEM MARKET MAP 70
5.4 PRICING ANALYSIS 70
FIGURE 25 AVERAGE SELLING PRICE TREND OF SCANNERS, BY REGION, 2018–2025 71
5.5 IMPACT OF NEW IVD REGULATION ON DIFFERENT MARKETS 71
FIGURE 26 TIMELINE AND TRANSITION TO NEW MDR AND IVDR 71
5.5.1 IMPACT ON CLINICAL LAB SERVICES 72
5.5.2 IMPACT ON IVD 73
5.5.3 IMPACT ON DIGITAL PATHOLOGY 73
5.6 TECHNOLOGY ANALYSIS 73
5.7 ARTIFICIAL INTELLIGENCE (AI) IN DIGITAL PATHOLOGY 74
5.7.1 LABEL-FREE IMAGING IN DIGITAL PATHOLOGY 74
5.7.2 COMPUTATIONAL IMAGE ANALYSIS IN DIGITAL PATHOLOGY 75
5.8 PORTER’S FIVE FORCES ANALYSIS 75
5.8.1 THREAT OF NEW ENTRANTS 75
5.8.2 THREAT OF SUBSTITUTES 75
5.8.3 BARGAINING POWER OF SUPPLIERS 75
5.8.4 BARGAINING POWER OF BUYERS 76
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.9 KEY CONFERENCES & EVENTS, 2023–2024 76
TABLE 5 DIGITAL PATHOLOGY MARKET: DETAILED LIST OF CONFERENCES & EVENTS 76
5.10 TARIFF AND REGULATORY ANALYSIS 77
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.10.2 REGULATORY ANALYSIS 77
5.10.2.1 North America 77
5.10.2.1.1 US 77
TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION 78
TABLE 8 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 78
5.10.2.1.2 Canada 78
TABLE 9 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 79
5.10.2.2 Europe 79
TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES 79
FIGURE 27 EUROPE: IVDR TIMELINE 80
5.10.2.3 Asia Pacific 80
5.10.2.3.1 Japan 80
TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 80
5.10.2.3.2 China 81
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 81
5.10.2.3.3 India 81
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 82
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS 82
TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DIGITAL PATHOLOGY PRODUCTS (%) 82
5.11.2 BUYING CRITERIA 83
FIGURE 29 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS 83
TABLE 14 KEY BUYING CRITERIA FOR DIGITAL PATHOLOGY PRODUCTS 83
5.12 PATENT ANALYSIS 83
5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 83
FIGURE 30 TOP PATENT OWNERS AND APPLICANTS: DIGITAL PATHOLOGY MARKET (JANUARY 2011–FEBRUARY 2023) 84
FIGURE 31 TOP APPLICANT JURISDICTIONS FOR DIGITAL PATHOLOGY MARKET (JANUARY 2011–FEBRUARY 2023) 85
5.12.2 PATENT PUBLICATION TRENDS FOR DIGITAL PATHOLOGY MARKET 85
FIGURE 32 PATENT ANALYSIS: DIGITAL PATHOLOGY MARKET (JANUARY 2011–FEBRUARY 2023) 85
TABLE 15 LIST OF PATENTS/PATENT APPLICATIONS IN DIGITAL PATHOLOGY MARKET, 2020–2023 86
6 DIGITAL PATHOLOGY MARKET, BY PRODUCT 89
6.1 INTRODUCTION 90
TABLE 16 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 90
6.2 SCANNERS 90
TABLE 17 SCANNING MAGNIFICATION AND APPLICATIONS 91
TABLE 18 DIGITAL PATHOLOGY SCANNERS OFFERED BY KEY MARKET PLAYERS 91
TABLE 19 DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE,
2021–2028 (USD MILLION) 92
TABLE 20 DIGITAL PATHOLOGY SCANNERS MARKET, BY COUNTRY,
2021–2028 (USD MILLION) 93
6.2.1 BRIGHTFIELD SCANNERS 93
6.2.1.1 Ideal solutions for small laboratories 93
TABLE 21 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS 94
TABLE 22 BRIGHTFIELD SCANNERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.2.2 OTHER SCANNERS 95
TABLE 23 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS 95
TABLE 24 OTHER SCANNERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
6.3 SOFTWARE 96
TABLE 25 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS 97
TABLE 26 DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 97
TABLE 27 DIGITAL PATHOLOGY SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.3.1 INTEGRATED SOFTWARE 98
6.3.1.1 Includes various modules for different digital pathology applications 98
TABLE 28 INTEGRATED SOFTWARE OFFERED BY KEY MARKET PLAYERS 99
TABLE 29 INTEGRATED SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
6.3.2 STANDALONE SOFTWARE 100
TABLE 30 STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 31 STANDALONE SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
6.3.2.1 Information management software 101
6.3.2.1.1 Enables comprehensive integration with information systems of any institute 101
TABLE 32 INFORMATION MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS 101
TABLE 33 INFORMATION MANAGEMENT SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
6.3.2.2 Image analysis software 102
6.3.2.2.1 Provides easy-to-use solutions for quantitative evaluation of brightfield slides 102
TABLE 34 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS 103
TABLE 35 IMAGE ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.4 STORAGE SYSTEMS 104
6.4.1 NEED FOR SAFE AND RELIABLE STORAGE OF HIGH-QUALITY IMAGES TO DRIVE MARKET 104
TABLE 36 STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS 104
TABLE 37 STORAGE SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
7 DIGITAL PATHOLOGY MARKET, BY TYPE 106
7.1 INTRODUCTION 107
TABLE 38 DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
7.2 HUMAN PATHOLOGY 107
7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO DRIVE MARKET 107
TABLE 39 HUMAN DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
7.3 VETERINARY PATHOLOGY 108
7.3.1 REDUCTION IN TURNAROUND TIME FOR ANIMAL DISEASE DIAGNOSIS TO DRIVE MARKET 108
TABLE 40 VETERINARY DIGITAL PATHOLOGY MARKET, BY COUNTRY,
2021–2028 (USD MILLION) 109
8 DIGITAL PATHOLOGY MARKET, BY APPLICATION 110
8.1 INTRODUCTION 111
TABLE 41 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 42 PRODUCT CROSS-MAPPING FOR DIFFERENT APPLICATIONS 111
8.2 DRUG DISCOVERY 111
8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET 111
TABLE 43 APPLICATIONS OF DIGITAL PATHOLOGY IN DRUG DISCOVERY 112
TABLE 44 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 113
8.3 DISEASE DIAGNOSIS 113
8.3.1 USE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DIGITAL PATHOLOGY SOLUTIONS TO PROPEL MARKET 113
TABLE 45 DIGITAL PATHOLOGY MARKET FOR DISEASE DIAGNOSIS, BY COUNTRY, 2021–2028 (USD MILLION) 114
8.4 TRAINING & EDUCATION 115
8.4.1 DIGITAL PATHOLOGY CAN IMPROVE EDUCATION & TRAINING PROVIDED TO PATHOLOGISTS IN ACADEMIC INSTITUTES 115
TABLE 46 DIGITAL PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY, 2021–2028 (USD MILLION) 115
9 DIGITAL PATHOLOGY MARKET, BY END USER 116
9.1 INTRODUCTION 117
TABLE 47 DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 117
TABLE 48 PRODUCT CROSS-MAPPING FOR DIFFERENT END USERS 117
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
9.2.1 RISING USE OF DIGITAL PATHOLOGY IN DRUG DEVELOPMENT TO DRIVE MARKET 117
TABLE 49 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 118
9.3 HOSPITALS & REFERENCE LABORATORIES 119
9.3.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 119
TABLE 50 HOSPITAL DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS 119
TABLE 51 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 120
9.4 ACADEMIC & RESEARCH INSTITUTES 121
9.4.1 INCREASING INVESTMENTS FOR RESEARCH IN DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH 121
TABLE 52 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 122

10 DIGITAL PATHOLOGY MARKET, BY REGION 123
10.1 INTRODUCTION 124
FIGURE 33 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 124
TABLE 53 DIGITAL PATHOLOGY MARKET, BY REGION, 2021–2028 (USD MILLION) 125
10.2 NORTH AMERICA 125
10.2.1 IMPACT OF RECESSION ON NORTH AMERICAN DIGITAL PATHOLOGY MARKET 125
FIGURE 34 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT 126
TABLE 54 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 55 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 56 NORTH AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 57 NORTH AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 58 NORTH AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 59 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 60 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 61 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.2.2 US 129
10.2.2.1 Rapidly increasing geriatric population and growing prevalence of chronic diseases to drive market 129
TABLE 62 US: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 130
TABLE 63 US: KEY MACROINDICATORS 131
TABLE 64 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
TABLE 65 US: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 66 US: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 67 US: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 68 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 69 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 70 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.2.3 CANADA 133
10.2.3.1 Increasing government initiatives for cancer awareness to drive market growth 133
TABLE 71 CANADA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 134
TABLE 72 CANADA: DIGITAL PATHOLOGY INITIATIVES AND FUNDING 135
TABLE 73 CANADA: KEY MACROINDICATORS 135
TABLE 74 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 136
TABLE 75 CANADA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 76 CANADA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 77 CANADA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 78 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 79 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 80 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 138
10.3 EUROPE 138
10.3.1 IMPACT OF RECESSION ON EUROPEAN DIGITAL PATHOLOGY MARKET 138
TABLE 81 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 82 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
TABLE 83 EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 84 EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 85 EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 86 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 87 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 88 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.3.2 UK 142
10.3.2.1 Rising government funding and initiatives to drive market 142
TABLE 89 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 143
TABLE 90 UK: KEY MACROINDICATORS 143
TABLE 91 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 143
TABLE 92 UK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 93 UK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 94 UK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 95 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 96 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 145
TABLE 97 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 145
10.3.3 GERMANY 146
10.3.3.1 High healthcare expenditure and supportive research initiatives to drive market 146
TABLE 98 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 146
TABLE 99 GERMANY: KEY MACROINDICATORS 147
TABLE 100 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 147
TABLE 101 GERMANY: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 102 GERMANY: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 103 GERMANY: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 104 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 105 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 106 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 149
10.3.4 SWEDEN 149
10.3.4.1 Increasing prevalence of chronic diseases to support market growth 149
TABLE 107 SWEDEN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 150
TABLE 108 SWEDEN: KEY MACROINDICATORS 150
TABLE 109 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151
TABLE 110 SWEDEN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 111 SWEDEN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 112 SWEDEN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 113 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 114 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 115 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 153
10.3.5 DENMARK 153
10.3.5.1 Increasing deployment of digital pathology solutions to support market growth 153
TABLE 116 DENMARK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 154
TABLE 117 DENMARK: KEY MACROINDICATORS 154
TABLE 118 DENMARK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 119 DENMARK: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 120 DENMARK: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 121 DENMARK: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 122 DENMARK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 123 DENMARK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156
TABLE 124 DENMARK: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.3.6 FRANCE 157
10.3.6.1 Increasing government funding and favorable insurance system to drive adoption 157
TABLE 125 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 157
TABLE 126 FRANCE: KEY MACROINDICATORS 158
TABLE 127 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 158
TABLE 128 FRANCE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 129 FRANCE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 130 FRANCE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 131 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 132 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 133 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.3.7 REST OF EUROPE 160
TABLE 134 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 135 REST OF EUROPE: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 136 REST OF EUROPE: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 137 REST OF EUROPE: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 138 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 139 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163
TABLE 140 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 163
10.4 ASIA PACIFIC 163
10.4.1 IMPACT OF RECESSION ON ASIA PACIFIC DIGITAL PATHOLOGY MARKET 163
FIGURE 35 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT 164
TABLE 141 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 142 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 165
TABLE 143 ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 144 ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 145 ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 146 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 147 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 167
TABLE 148 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 167
10.4.2 CHINA 167
10.4.2.1 Rising geriatric population to drive demand for digital pathology products 167
TABLE 149 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 168
TABLE 150 CHINA: KEY MACROINDICATORS 168
TABLE 151 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 169
TABLE 152 CHINA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 153 CHINA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 154 CHINA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 155 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 156 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 157 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 171
10.4.3 JAPAN 171
10.4.3.1 Advanced healthcare infrastructure to support market growth 171
TABLE 158 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 172
TABLE 159 JAPAN: KEY MACROINDICATORS 172
TABLE 160 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172
TABLE 161 JAPAN: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 162 JAPAN: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 163 JAPAN: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 164 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 174
TABLE 165 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 166 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 174
10.4.4 INDIA 175
10.4.4.1 Increasing awareness regarding benefits of digital pathology solutions to drive market 175
TABLE 167 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 176
TABLE 168 INDIA: KEY MACROINDICATORS 176
TABLE 169 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176
TABLE 170 INDIA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 171 INDIA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 172 INDIA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 173 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 178
TABLE 174 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 175 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 178
10.4.5 REST OF ASIA PACIFIC 179
TABLE 176 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 179
TABLE 177 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 178 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 179 REST OF ASIA PACIFIC: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 180 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 181 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 182 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 181
10.5 LATIN AMERICA 182
10.5.1 IMPACT OF RECESSION ON LATIN AMERICAN DIGITAL PATHOLOGY MARKET 182
TABLE 183 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 184 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 183
TABLE 185 LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 186 LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 187 LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 188 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 189 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184
TABLE 190 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 185
10.5.2 BRAZIL 185
10.5.2.1 Rising initiatives to drive adoption of digital pathology solutions 185
TABLE 191 BRAZIL: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 186
TABLE 192 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 186
TABLE 193 BRAZIL: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 194 BRAZIL: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 195 BRAZIL: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 196 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 197 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 188
TABLE 198 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 188
10.5.3 MEXICO 188
10.5.3.1 Rising burden of cancer to drive uptake of digital pathology solutions 188
TABLE 199 MEXICO: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 189
TABLE 200 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189
TABLE 201 MEXICO: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 202 MEXICO: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 203 MEXICO: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 204 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 205 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 206 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 191
10.5.4 REST OF LATIN AMERICA 192
TABLE 207 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192
TABLE 208 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 209 REST OF LATIN AMERICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 210 REST OF LATIN AMERICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 211 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 212 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 194
TABLE 213 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 194
10.6 MIDDLE EAST & AFRICA 194
10.6.1 INFRASTRUCTURAL DEVELOPMENTS TO SUPPORT MARKET GROWTH 194
10.6.2 IMPACT OF RECESSION ON MIDDLE EAST & AFRICAN DIGITAL PATHOLOGY MARKET 195
TABLE 214 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196
TABLE 215 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SCANNERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 216 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 217 MIDDLE EAST AND AFRICA: STANDALONE SOFTWARE MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 218 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 219 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 197
TABLE 220 MIDDLE EAST AND AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2021–2028 (USD MILLION) 198
11 COMPETITIVE LANDSCAPE 199
11.1 OVERVIEW 199
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 199
FIGURE 36 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET 200
11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 201
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL PATHOLOGY MARKET 202
11.4 COMPETITIVE BENCHMARKING 202
TABLE 221 FOOTPRINT ANALYSIS OF COMPANIES IN DIGITAL PATHOLOGY MARKET 202
TABLE 222 PRODUCT FOOTPRINT ANALYSIS OF COMPANIES 204
TABLE 223 APPLICATION FOOTPRINT ANALYSIS OF COMPANIES 205
TABLE 224 END-USER FOOTPRINT ANALYSIS OF COMPANIES 206
TABLE 225 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES 207
11.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 208
11.5.1 STARS 208
11.5.2 EMERGING LEADERS 208
11.5.3 PERVASIVE PLAYERS 208
11.5.4 PARTICIPANTS 208
FIGURE 38 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2022) 209
11.6 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS 209
11.6.1 PROGRESSIVE COMPANIES 209
11.6.2 DYNAMIC COMPANIES 209
11.6.3 STARTING BLOCKS 210
11.6.4 RESPONSIVE COMPANIES 210
FIGURE 39 DIGITAL PATHOLOGY MARKET: COMPANY EVALUATION QUADRANT FOR SMES/ STARTUPS (2022) 210
11.7 MARKET SHARE ANALYSIS 211
FIGURE 40 DIGITAL PATHOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 212
TABLE 226 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION 212
11.8 COMPETITIVE SCENARIO 213
11.8.1 PRODUCT LAUNCHES AND APPROVALS 213
TABLE 227 KEY PRODUCT LAUNCHES AND APPROVALS 214
11.8.2 DEALS 214
TABLE 228 KEY DEALS 214
12 COMPANY PROFILES 216
12.1 KEY PLAYERS 216
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION 216
TABLE 229 DANAHER CORPORATION: BUSINESS OVERVIEW 216
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 217
12.1.2 KONINKLIJKE PHILIPS N.V. 220
TABLE 230 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW 220
FIGURE 42 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 221
12.1.3 HAMAMATSU PHOTONICS K.K. 224
TABLE 231 HAMAMATSU PHOTONICS K.K.: BUSINESS OVERVIEW 224
FIGURE 43 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2022) 225
12.1.4 F. HOFFMANN-LA ROCHE LTD. 227
TABLE 232 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 227
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 228
12.1.5 SECTRA AB 230
TABLE 233 SECTRA AB: BUSINESS OVERVIEW 230
FIGURE 45 SECTRA AB: COMPANY SNAPSHOT (2021) 231
12.1.6 AKOYA BIOSCIENCES, INC. 235
TABLE 234 AKOYA BIOSCIENCES, INC.: BUSINESS OVERVIEW 235
FIGURE 46 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2022) 236
12.1.7 3DHISTECH LTD. 238
TABLE 235 3DHISTECH LTD.: BUSINESS OVERVIEW 238
12.1.8 APOLLO ENTERPRISE IMAGING CORP. 240
TABLE 236 APOLLO ENTERPRISE IMAGING CORP.: BUSINESS OVERVIEW 240
12.1.9 XIFIN, INC. 241
TABLE 237 XIFIN, INC.: BUSINESS OVERVIEW 241
12.1.10 HURON DIGITAL PATHOLOGY 242
TABLE 238 HURON DIGITAL PATHOLOGY: BUSINESS OVERVIEW 242
12.1.11 HOLOGIC, INC. 244
TABLE 239 HOLOGIC, INC.: BUSINESS OVERVIEW 244
FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 245
12.1.12 CORISTA 247
TABLE 240 CORISTA: BUSINESS OVERVIEW 247
12.1.13 INDICA LABS INC. 249
TABLE 241 INDICA LABS INC.: BUSINESS OVERVIEW 249
12.1.14 OBJECTIVE PATHOLOGY SERVICES LIMITED 251
TABLE 242 OBJECTIVE PATHOLOGY SERVICES LIMITED: BUSINESS OVERVIEW 251
12.1.15 OPTRASCAN INC. 252
TABLE 243 OPTRASCAN INC.: BUSINESS OVERVIEW 252
12.1.16 GLENCOE SOFTWARE, INC. 254
TABLE 244 GLENCOE SOFTWARE, INC.: BUSINESS OVERVIEW 254
12.1.17 AIFORIA TECHNOLOGIES OYJ 255
TABLE 245 AIFORIA TECHNOLOGIES OYJ: BUSINESS OVERVIEW 255
12.1.18 PAIGE AI, INC. 257
TABLE 246 PAIGE AI, INC.: BUSINESS OVERVIEW 257
12.1.19 FUJIFILM HOLDINGS CORPORATION 259
TABLE 247 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 259
FIGURE 48 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021) 260
12.1.20 PROSCIA INC. 262
TABLE 248 PROSCIA, INC.: BUSINESS OVERVIEW 262
12.2 OTHER PLAYERS 265
12.2.1 PATHAI, INC. 265
12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD. 265
12.2.3 MIKROSCAN TECHNOLOGIES, INC. 266
12.2.4 MOTIC DIGITAL PATHOLOGY 266
12.2.5 KANTERON SYSTEMS 266
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 267
13.1 DISCUSSION GUIDE 267
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 271
13.3 CUSTOMIZATION OPTIONS 273
13.4 RELATED REPORTS 273
13.5 AUTHOR DETAILS 274

ページTOPに戻る

Table of Contents

Summary

The global digital pathology market is projected to reach USD 1.8 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 13.6% during the forecast period. Growth in the digital pathology market is mainly driven by factors such as the growing applications of digital pathology in drug development , growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening.
On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent.

Software segment is projected to grow at the highest CAGR during the forecast period By product, the global digital pathology market is segmented into scanners, software, and storage systems. The software segment is projected to grow at the highest CAGR during the forecast period.This can be attributed to the high adoption of integrated software by pathologists, and increased adoption of digital pathology software solutions in various healthcare facilities for remote primary diagnosis.
Human pathology segment is projected to grow at the highest CAGR during the forecast period By type, the digital pathology market is segmented into human pathology and veterinary pathology. In 2023, the human pathology segment is projected to grow at the highest CAGR due to the growing awareness of early cancer diagnosis in emerging economies, and growing collaborations among academic research institutes, universities, and pathology laboratories.

Drug discovery segment is projected to grow at the highest CAGR during the forecast period
By application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. In 2023, drug discovery application segment is projected to grow at the highest CAGR during the forecast period. The growth in high throughput screening and imaging, and the rising number of preclinical & clinical studies are the major factors responsible for the large share and high growth rate of the drug discovery application segment.

Pharmaceutical & biotechnology companies end user segment is projected to account for the largest share of the digital pathology market By end user, the digital pathology market is broadly segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. Pharmaceutical & biotechnology companies are the largest end users of the digital pathology market. In 2023, the pharmaceutical & biotechnology companies segment is projected to account for the largest share of the digital pathology market due to growing use of digital pathology for drug toxicology testing. Biotechnology companies use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

By region, North America is projected to account for the largest share of the digital pathology market
By region,North America accounted for the largest share of the digital pathology market in 2022. During the forecast period this market is expected to grow at the highest rate. Factors such as the growing geriatric population, rising prevalence of cancer, the presence of high-quality infrastructure, and the favorable reimbursement in the region are driving the growth of the market in North America.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 45%, and Tier 3 – 20% • By Designation: C-level – 35%, Director-level – 25%, and Others – 40% • By Region: North America - 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%
Some of the prominent players operating in the digital pathology market include Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), , Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), and Kanteron Systems (Spain).

Research Coverage
This report studies the digital pathology market based on type, application, product, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
This report provides insights into the following pointers:

Analysis of key drivers (increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, growing applications of digital pathology in drug development and companion diagnostics, growing awareness of early cancer diagnosis in emerging economies, and recommendations for cancer screening),opportunities (introduction of affordable scanners for private pathology practices, growing demand for personalized medicine, and high growth opportunities in emerging economies) and challenges (shortage of trained pathologists) influencing the growth of digital pathology market.

Market Penetration: Comprehensive information on product portfolios offered by the top players in the global digital pathology market . The report analyzes this market by product, type, application, end user, and region
Product Development/Innovation: Detailed insights on upcoming trends and product launches in the global digital pathology market
Market Development: Comprehensive information on the lucrative emerging markets by product, type, application, end user, and region
Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global digital pathology market
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global digital pathology market

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets社のHealthcare IT分野での最新刊レポート

本レポートと同じKEY WORD（diagnosis drug）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets社のHealthcare IT分野での最新刊レポート

本レポートと同じKEY WORD（diagnosis drug）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?